Table 5.
GSH/GSSG ratio and their evolution (mean±SD).
| Product | V1 | V2 | V3 | ΔV2–V1 | ΔV3–V2 | ΔV3–V1 |
|---|---|---|---|---|---|---|
| NAC (n=20) | 50.03±14.02 | 46.25±7.17 | 56.44±13.74 | −3.79±11.39 | 9.71±10.81 | 7.38±11.12 |
| Oral GSH (n=20) | 51.68±11.04 | 51.54±14.28 | 44.76±14.23 | −0.91±9.35 | −6.31±17.41 | −6.92±15.90 |
| Sublingual (n=20) | 47.55±12.50 | 53.69±13.84 | 56.97±16.22 | 6.15±10.41 | 3.27±14.75 | 9.42±14.62 |
| Comparison NAC/PO | p=0.28 | p=0.20 | p=0.03 | p=0.29 | p=0.06 | p=0.01 |
| Comparison NAC/SL | p=0.22 | p=0.03 | p=0.37 | p=0.02 | p=0.22 | p=0.20 |
| Comparison PO/SL | p=0.11 | p=0.20 | p=0.02 | p=0.03 | p=0.07 | p=0.002 |